CY1109044T1 - Εμβολιο και η χρηση του για τη θεραπεια της πλαγιας myατροφικης σκληρυνσης - Google Patents

Εμβολιο και η χρηση του για τη θεραπεια της πλαγιας myατροφικης σκληρυνσης

Info

Publication number
CY1109044T1
CY1109044T1 CY20091100485T CY091100485T CY1109044T1 CY 1109044 T1 CY1109044 T1 CY 1109044T1 CY 20091100485 T CY20091100485 T CY 20091100485T CY 091100485 T CY091100485 T CY 091100485T CY 1109044 T1 CY1109044 T1 CY 1109044T1
Authority
CY
Cyprus
Prior art keywords
cop
vaccine
treatment
tyr
glu
Prior art date
Application number
CY20091100485T
Other languages
English (en)
Inventor
Michal Eisenbach-Schwartz
Esther Yoles
Original Assignee
Yeda Research And Development Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Company, Ltd. filed Critical Yeda Research And Development Company, Ltd.
Publication of CY1109044T1 publication Critical patent/CY1109044T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Ένα εμβόλιο για μείωση της προόδου της ασθένειας, ή/και την προστασία του εκφυλισμού του κινητικού νεύρου, ή/και την προστασία από την γλουταμινική τοξικότητα σε ασθενείς με την ασθένεια κινητικών νευρώνων (MND), ιδιαίτερα την πλάγια μυατροφική σκλήρυνση (ALS), που περιλαμβάνει ένα δραστικό παράγοντα που επιλέγεται από την ομάδα που αποτελείται από Cop 1, ένα συγγενές με το Copl πεπτίδιο, ένα συγγενές με το Cop 1 πολυπεπτίδιο, και poly-Glu, Tyr. Ο δραστικός παράγοντας είναι κατά προτίμηση Cop 1 ή poly-Glu, Tyr, και μπορεί να χορηγηθεί με ή χωρίς επικουρικό.
CY20091100485T 2001-12-06 2009-05-06 Εμβολιο και η χρηση του για τη θεραπεια της πλαγιας myατροφικης σκληρυνσης CY1109044T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33613901P 2001-12-06 2001-12-06
EP02788511A EP1429800B1 (en) 2001-12-06 2002-12-05 Vaccine and use thereof for treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
CY1109044T1 true CY1109044T1 (el) 2014-07-02

Family

ID=23314742

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100485T CY1109044T1 (el) 2001-12-06 2009-05-06 Εμβολιο και η χρηση του για τη θεραπεια της πλαγιας myατροφικης σκληρυνσης

Country Status (24)

Country Link
US (1) US7351686B2 (el)
EP (1) EP1429800B1 (el)
JP (1) JP4542339B2 (el)
KR (1) KR20040081431A (el)
CN (2) CN1617736A (el)
AT (1) ATE422362T1 (el)
AU (1) AU2002353486B2 (el)
CA (1) CA2469092C (el)
CY (1) CY1109044T1 (el)
DE (1) DE60231131D1 (el)
DK (1) DK1429800T3 (el)
ES (1) ES2322566T3 (el)
HK (1) HK1067043A1 (el)
HU (1) HU228207B1 (el)
IL (1) IL160105A0 (el)
IS (1) IS2670B (el)
MX (1) MXPA04005537A (el)
NO (1) NO336231B1 (el)
NZ (1) NZ533356A (el)
PL (1) PL205469B1 (el)
PT (1) PT1429800E (el)
RU (1) RU2303996C2 (el)
SI (1) SI1429800T1 (el)
WO (1) WO2003047500A2 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
CA2512735C (en) * 2003-01-07 2016-03-08 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
WO2005056574A2 (en) 2003-12-09 2005-06-23 Yeda Research And Development Co. Ltd. Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
EP2301569B1 (en) 2003-11-12 2018-05-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
US20070244056A1 (en) * 2004-03-03 2007-10-18 Liat Hayardeny Combination Therapy With Glatiramer Acetate and Riluzole
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
ES2560448T3 (es) * 2004-05-07 2016-02-19 Ares Trading S.A. Procedimientos de tratamiento de enfermedades con copolímeros aleatorios
JP5241012B2 (ja) 2005-07-15 2013-07-17 ノバルティス アーゲー Ｐａｍｐｓ、病原体関連分子パターン
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
EP2195008A1 (en) 2007-09-24 2010-06-16 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2013084236A1 (en) * 2011-12-05 2013-06-13 Ben-Gurion University Of The Negev Research And Development Authority Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (als)
KR20140145173A (ko) * 2012-03-26 2014-12-22 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커
WO2014037952A1 (en) 2012-09-10 2014-03-13 Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3849650A (en) 1973-03-29 1974-11-19 Picker Corp Automatic x-ray inspection system
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
SE505316C2 (sv) 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
US20030108528A1 (en) * 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1039929A1 (en) 1998-07-21 2000-10-04 YEDA RESEARCH AND DEVELOPMENT Co. Ltd. Activated t-cells and their uses
AU766498B2 (en) 1998-07-23 2003-10-16 President And Fellows Of Harvard College, The Synthetic peptides and methods of use for autoimmune disease therapies
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
ATE314860T1 (de) * 2000-06-07 2006-02-15 Yeda Res & Dev Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy

Also Published As

Publication number Publication date
IS2670B (is) 2010-09-15
AU2002353486A1 (en) 2003-06-17
JP4542339B2 (ja) 2010-09-15
ATE422362T1 (de) 2009-02-15
NZ533356A (en) 2006-10-27
CN1617736A (zh) 2005-05-18
IL160105A0 (en) 2004-06-20
DE60231131D1 (de) 2009-03-26
CN102151330B (zh) 2017-04-12
WO2003047500A3 (en) 2004-03-18
HUP0500039A3 (en) 2010-01-28
HK1067043A1 (en) 2005-04-01
WO2003047500A2 (en) 2003-06-12
DK1429800T3 (da) 2009-04-27
HU228207B1 (hu) 2013-01-28
SI1429800T1 (sl) 2009-08-31
AU2002353486B2 (en) 2009-01-15
EP1429800A4 (en) 2006-03-22
NO20042833L (no) 2004-08-12
US20050220802A1 (en) 2005-10-06
KR20040081431A (ko) 2004-09-21
PL205469B1 (pl) 2010-04-30
EP1429800B1 (en) 2009-02-11
RU2303996C2 (ru) 2007-08-10
IS7296A (is) 2004-06-03
CA2469092C (en) 2013-02-19
RU2004120536A (ru) 2005-03-27
JP2005515198A (ja) 2005-05-26
US7351686B2 (en) 2008-04-01
PT1429800E (pt) 2009-04-27
ES2322566T3 (es) 2009-06-23
HUP0500039A2 (hu) 2005-03-29
NO336231B1 (no) 2015-06-22
EP1429800A2 (en) 2004-06-23
PL370070A1 (en) 2005-05-16
CN102151330A (zh) 2011-08-17
MXPA04005537A (es) 2004-11-01
CA2469092A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
CY1109044T1 (el) Εμβολιο και η χρηση του για τη θεραπεια της πλαγιας myατροφικης σκληρυνσης
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
CY1108331T1 (el) Προληψη και θεραπεια αμυλοειδογονου νοσου
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
CY1108874T1 (el) ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ
CY1111872T1 (el) Συνθεσεις υποτασικου λιπιδιου (προσταγλανδινης) και τιμολολης - σχετικες μεθοδοι χρησης
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
CY1108536T1 (el) Ιμιδαζοκουινολινες υποκατεστημενες με σουλφοναμιδιο και σουλφαμιδιο
CY1111237T1 (el) Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
CY1114445T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης για χρηση στη θεραπευτικη αγωγη ή προληψη αυτοανοσων ασθενειων
CY1109981T1 (el) Αναλογα του gaba για την προληψη και αγωγη γαστρεντερικης βλαβης
ATE419872T1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
CY1108740T1 (el) ΕΞΑΝΘΡΩΠΙΣΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΤΑ ΟΠΟΙΑ ΑΝΑΓΝΩΡΙΖΟΥΝ ΤΟ ΠΕΠΤΙΔΙΟ β-ΑΜΥΛΟΕΙΔΟΥΣ
CY1104988T1 (el) Μεθοδος αντιμετωπισης μολυνσεων του μεσου ωτος
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
DE69718150D1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
CY1118924T1 (el) Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE
CY1105629T1 (el) Πολυπεπτιδιο που επαγει αντισωματα εξουδετερωσης του ηιv
HUP0500642A2 (hu) Csökkentett toxicitású ciszplatin készítmények és eljárás alkalmazásukra
CY1108412T1 (el) Συνθεσεις εμβολιου που περιλαμβανουν omp85 πρωτεϊνες απο neisseria gonorrhoea και neisseria miningitidis
CY1105624T1 (el) Αντιγλαυκωματικο μεσο και χρηση αυτου